A drug used to induce abortions should be accessible by mail while the the federal Food & Drug Administration appeals an order lifting its in-person dispensing requirement during the Covid-19 pandemic, women’s health-care providers told a federal appeals court.
The providers, including the American College of Obstetricians & Gynecologists, filed a response Tuesday to the FDA’s request that the U.S. Court of Appeals for the Fourth Circuit allow it to enforce a requirement that mifepristone be distributed only through hospitals, clinics, and doctor’s offices until the court decides if an injunction against it was properly granted.
Mifepristone is one of ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.